Private capital backed the company enabling it to obtain approval from Health Canada in April 2016 for the start of growing at its 26,000 sq ft of growing space in Aylmer, Ontario.

And in June, it received a supplemental licence from Health Canada to produce medical cannabis oils, an important milestone to broaden its offering.

The same month it revealed an agreement with Aurora Cannabis, where the firm will supply Aurora with its surplus cannabis once all of its clients' current and future needs have been met.

In return, WeedMD can leverage Aurora's unit that deals with patient counselling.

Also in June it unveiled a partnership with Van der Pop to bring a leading female-focused brand to Canada and WeedMD expects to deliver medical cannabis under the Van der Pop brand to its Canadian patients starting in late 2017.

Hitting development goals...

Last month, the group said it was hitting the development goals it had promised, and posted revenue of $235,659 in its first quarter of sales - the three months to end June.

Revenues were mainly from the sale of dried medical cannabis and live cannabis plants.

A difficult but large market..

Broker Eight Capital noted that supplying clients in LTC (long term care) facilities was a difficult market to penetrate because of the complexity of patient care, but that client retention was "very strong".

It also reckons WeedMD could become a M&A (merger and acquisition) target to another group wishing to add a recurring revenue stream or another part of the value chain.

Seniors are increasingly looking for alternative therapies for illnesses like cancer, dementia and multiple sclerosis and there has been more science published on the benefits of cancer, notes the broker.

According to official numbers, Canada now has more people over 65 than children under 15.

"The growth rate of the population aged 65 years and older was 3.5% in 2014/15, which was around four times that of the total population.

"With the baby boomer generation now reaching 65 years old, this demographic will only increase in size going forward," it says.

What's it worth..?

Eight Capital has a target price of C$2.25 on the shares, which is a long way from the current price of C$0.87.

This is based on a multiple of six times' enterprise value/ EBITDA to 2021 estimates of underlying earnings (EBITDA) of C$35mln.

"The 6.0x multiple is at the lower end of our peer group range of 4.0x - 10.0x, due to WeedMD's earlier stage operation," the broker notes.

Shares have rocketed an impressive 470% in the last three months alone to stand at C$1.20

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

WeedMD Rx Inc. is a licensed producer of medical cannabis pursuant to the Access to Cannabis for Medical Purposes Regulations (ACMPR). WeedMD operates a 26,000 square foot, scalable production facility in Aylmer, Ontario with four acres of property for future...

WeedMD Rx Inc. is a licensed producer of medical cannabis pursuant to the Access to Cannabis for Medical Purposes Regulations (ACMPR). WeedMD operates a 26,000 square foot, scalable production facility in Aylmer, Ontario with four acres of property for future expansion. WeedMD is focused on providing consistent, quality medicine to the long-term care and assisted living markets in Canada through its comprehensive platform developed exclusively for that industry. WeedMD is dedicated to educating healthcare practitioners and furthering public understanding of the role medical cannabis can play as a viable alternative to prescription medication in relieving a variety of chronic medical conditions and illnesses.